Previously recorded as Park Therapeutics, Inc. (to 2025)
19 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2031
Next term end
14
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2031 · High confidence
Also notable
Ends Apr 2035 · High confidence
Also notable
Ends Feb 2037 · High confidence
Also notable
Ends Jan 2036 · High confidence
Also notable
Ends May 2033 · High confidence
Also notable
Ends May 2033 · High confidence
Also notable
Ends Jul 2032 · High confidence
Also notable
Ends May 2033 · High confidence
Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine
US 9,289,416
The most cited patent in this portfolio, cited by 45 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2031.
Process for the Preparation of 5-Fluorotryptophol
US 10,323,040
Granted 2019. Computed term ends 2035.
Titration of Cebranopadol
US 11,229,625
Granted 2022. Computed term ends 2037.
Cebranopadol for Treating Pain in Subjects with Impaired Hepatic And/Or Impaired Renal Function
US 10,022,353
Cited by 16 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
Pharmaceutical Composition Comprising (1r,4r)-6'-flouro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US 9,320,729
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2033.
Pharmaceutical Composition Comprising (1R,4R)-6'-Fluoro-N,N-DIMETHYL-4-Phenyl-4',9'-Dihydro-3'H-SPIRO [CYCLOHEXANE-1,1'-Pyrano-[3,4,B]INDOL]-4-Amine and Paracetamol or Propacetamol
US 11,311,504
Granted 2022. Computed term ends 2033.
Crystalline (1r, 4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
US 8,614,245
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2032. A terminal disclaimer caps this term to an earlier patent's.
Pharmaceutical Composition Comprising (1R,4R)-6'-Fluoro-N,N-DIMETHYL-4-Phenyl-4'9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano[3,4,B]INDOL]-4-Amine and a Gabapentinoid
US 9,320,725
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2033.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Process for the Preparation of 5-Fluorotryptophol (US 10,323,040) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine (US 9,289,416) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 3 fees due Oct 12 to 26, 2027 · next Oct 12
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 14 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,289,416 | Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine In force · High confidence | In force | High confidence | |
| US 10,912,763 | Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine In force · High confidence | In force | High confidence | |
| US 8,658,827 | Method for Synthesizing Substituted Aminocyclohexanone Compounds In force · High confidence | In force | High confidence | |
| US 8,614,245 | Crystalline (1r, 4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine In force · High confidence | In force | High confidence | |
| US 8,618,156 | Crystalline (1R,4R)-6'-Fluoro-N,N-DIMETHYL-4-Phenyl-4',9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano[3,4,B]INDOL]-4-Amine In force · High confidence | In force | High confidence | |
| US 8,912,343 | Solid Forms of (1 R,4R)-6' -Fluoro-(n, N-DIMETHYL)-4-Phenyl-4' ,9'-Dihydro-3'H-SPIRO[ CYCLOHEXANE-1,1 '-PYRANO-[3,4,B]INDOL]-4-Amine and Sulfuric Acid In force · High confidence | In force | High confidence | |
| US 8,779,160 | Process for the Preparation of (1R,4R)-6'-Fluoro-(N,N-DIMETHYL- and N-METHYL)-4-Phenyl-4',9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano-[3,4,B]INDOL]-4-Amine In force · High confidence | In force | High confidence | |
| US 8,895,604 | Solid forms of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3' H-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine hydrochloride In force · High confidence | In force | High confidence | |
| US 8,912,226 | Pharmaceutical Composition Comprising (1R,4R)-6'-Fluoro-N,N-DIMETHYL-4-Phenyl-4',9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano[3,4,B]INDOL]-4-Amine and a Nsar In force · High confidence | In force | High confidence | |
| US 9,320,725 | Pharmaceutical Composition Comprising (1R,4R)-6'-Fluoro-N,N-DIMETHYL-4-Phenyl-4'9'-Dihydro-3'H-SPIRO[CYCLOHEXANE-1,1'-Pyrano[3,4,B]INDOL]-4-Amine and a Gabapentinoid In force · High confidence | In force | High confidence |
Also on record, not counted in the 19: 1 patent in force now held by others · 5 patents ended · 3 applications pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.